This page covers AQA spec point 3.8.2.1 Most of a cell's DNA is not translated, which is within 3.8.2 Gene expression is controlled by a number of features

What are stem cells?

  • Stem cells are undifferentiated (unspecialised) cells, which are capable of continuously dividing into new stem cells or new specialised cells.
  • The types of specialised cells the stem cells can divide into depends on the cell’s ability to differentiate (stem cells’ potency)

Types of stem cells

Spec Point

  • Totipotent cells can divide and produce any type of body cell.
  • Totipotent cells occur only for a limited time in early mammalian embryos.
  • Pluripotent cells are found in embryos; multipotent and unipotent cells are found in mature mammals and can divide to form a limited number of different cell types.
  • Pluripotent stem cells can divide in unlimited numbers and can be used in treating human disorders.
  • Unipotent cells, exemplified by the formation of cardiomyocytes .
Stem cell diagram
  • Totipotent cells (all types of body cell)
    • Totipotent cells are formed from a zygote and only exist for a brief period of time (approximately 4 days in humans).
    • They have the ability to differentiate into all types of cells (including embryonic & placenta cells)
  • Pluripotent (all types excluding the embryonic & placenta tissue)
    • Pluripotent stem cells are found in embryos after 4 days - they are the inner mass of the blastocyst cell (see on diagram)
    • They have the ability to differentiate into any type of body cell, but not embryonic and placenta tissue
  • Adult stem cells, include:
    • Multipotent
      • Can develop into a limited number of specialised cells
      • e.g Haematopoietic Stem Cells, can differentiate into different blood cell types
    • Unipotent
      • Can only divide into one type of cell
      • e.g. Muscle stem cells make muscle fibres
      • e.g Epidermal (skin) stem cells make skin cells

Stem cells & differentiation

Spec Point

During development, totipotent cells translate only part of their DNA, resulting in cell specialisation.

  • Stem cells contain the same genes, but during development not all genes are expressed (i.e. not all are transcribed and translated).
  • Differentiation occurs because specific genes are switched on or off.
  • Signals (external or internal), such as chemical signals from neighbouring cells, trigger changes in gene expression.
  • Gene expression can be controlled by:
    • Transcription (DNA → mRNA)
    • Translation (mRNA → protein)
      • Prevention of translation of certain mRNA molecules
      • The proteins produced determine the cell’s structure and function
  • As cells become more specialised, these changes in gene expression become increasingly difficult to reverse.

Induced Pluripotent Stem Cells

Spec Point

Induced pluripotent stem cells (iPS cells) can be produced from adult somatic cells using appropriate protein transcription factors.

  • iPSCs are created by reprogramming specialised adult cells back to pluripotent state
  • iPSCs
    • Have the ability to self-renew
    • Can differentiate into any body cell type
    • Function similarly to embryonic stem cells, but without the ethical concerns since embryos are not destroyed as part of this process
    • Made from patient’s own cells (genetically identical) so reduce the risk of immune rejection

Brief outline of the process below:

  1. Start with a specialised adult cell
    • Blood cells are commonly used for this
  2. Introduce genes that code for pluripotency transcription factors
  3. Reprogramming occurs
    • Transcription factors switch on genes associated with pluripotency and switch off genes for differentiation
    • Cell loses its specialised identity - it becomes pluripotent

Stem Cells to Treat Diseases

Spec Point

Evaluate the use of stem cells in treating human disorders.

Given the properties of pluripotent cells, ability to self renew and differentiate into any body cell (excluding embryonic / placenta), there are many potential uses for these in treatments.

Stem cellAdvantagesDisadvantages
EmbryonicPluripotent – can form any body cell
Rapid division → large numbers of cells
Ethical issues (embryo destruction)
Not patient-specific → immune rejection risk
Risk of tumour formation
Induced pluripotent (iPSC)Pluripotent
No ethical issues
Patient-specific → reduced rejection
Used for disease models & drug testing
Possible genetic/epigenetic changes
Tumour risk
Expensive & complex
Long-term safety unknown
Adult (somatic)No ethical issues
Often patient-specific
Already used clinically
Multipotent or unipotent
Limited cell types
Difficult to isolate & culture

Why do adult stem cells have a much lower tumour risk?

Embryonic and induced pluripotent stem cells have a higher risk of tumour formation because they are undifferentiated and can divide rapidly. Adult stem cells have limited potency, so they divide more slowly and are more tightly regulated.

AO3 evaluation question tips

  • Consider both the pros and cons of the statement
  • Interrogate the methodology (e.g. Is the experiment long enough? Was it done on humans or only mice?)
  • Interrogate the data (e.g. Is it significant? Was a statistical test used? Is the sample size large enough?)

Exam Question Practice

Question 1

Myelodysplastic syndromes (MDS) are a group of malignant cancers. In MDS, the bone marrow does not produce healthy blood cells.

Haematopoietic stem cell transplantation (HSCT) is one treatment for MDS. In HSCT, the patient receives stem cells from the bone marrow of a person who does not have MDS. Before the treatment starts, the patient’s faulty bone marrow is destroyed.

For some patients, HSCT is an effective treatment for MDS. Explain how.

(3 marks)
Hint

Think about what the new stem cells produce, and why this is a long-term solution.

Answer

Mark Scheme

  1. Produce healthy (blood) cells (1 mark)
  2. No MDS/faulty/cancerous (blood) cells (1 mark)
  3. Stem cells divide/replicate (1 mark)
Comments from mark scheme
  • Produce only healthy/normal (blood) cells = two marks (points 1 and 2)
  • Accept produce ‘normal’/non-MDS cells
  • Accept no (cancerous) tumour
  • Ignore reference to totipotent/pluripotent/multipotent/unipotent
  • Accept ‘clone’ for divide
Question 2

Haematopoietic stem cell transplantation (HSCT) is a long-term treatment for SCD. In HSCT, the patient receives stem cells from the bone marrow of a person who does not have SCD. The donor is often the patient’s brother or sister. Before the treatment starts, the patient’s faulty bone marrow cells have to be destroyed.

Use this information to explain how HSCT is an effective long-term treatment for SCD.

(3 marks)
Hint

Think about what the new cells produce, and why using a sibling donor is mentioned.

Answer

Mark Scheme

  1. Produce healthy (red blood) cells OR Produce (normal) polypeptide/haemoglobin (1 mark)
  2. No sickle/faulty/SCD (red blood) cells (produced) OR No defective polypeptide/haemoglobin (1 mark)
  3. Stem/marrow cells (continuously) divide/replicate OR Less chance of rejection (from brother/sister) (1 mark)
Comments from mark scheme
  • Produce only healthy (red blood) cells is only equivalent to mark point 1
  • Accept produce ‘normal’/non-SCD cells
  • Ignore type of stem cell e.g. pluripotent
  • Differentiate is not equivalent to divide/replicate
Question 3

A new long-term treatment for SCD involves the use of gene therapy. Figure 2 shows some of the stages involved in this treatment in a child with SCD.

Some scientists have concluded that this method of gene therapy will be a more effective long-term treatment for SCD than HSCT. Use all the information provided to evaluate this conclusion.

(3 marks)
Hint

Evaluate = points FOR and AGAINST. Think about what gene therapy avoids, and what risks it introduces.

Answer

Mark Scheme

For gene therapy:

  1. No destruction of bone marrow OR No destruction of stem cells (1 mark)
  2. Donors are not required (1 mark)
  3. Less/no chance of rejection (own stem cells) (1 mark)

Against gene therapy:

  1. Sickle/faulty (red blood) cells still produced (1 mark)
  2. Immune response against genetically modified cells/virus OR Long-term effect not known (as is new treatment) OR Virus could cause side effects (1 mark)
Comments from mark scheme
  • Max 2 marks for marking points 1, 2 and 3
  • Accept no destruction of faulty bone marrow unless context indicates this is against gene therapy
  • Stating ‘only own cells used’ is not equivalent
  • Accept ‘virus could cause problems’ or ‘risk(s) with virus’